Avadel Pharmaceuticals (AVDL) announced the appointment of Susan Rodriguez as COO. In this newly created role, Rodriguez will lead all aspects of the company’s commercial strategy, structure, organization, and related operations, including supply chain.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVDL:
- Avadel Pharmaceuticals Sees Strong Q1 Growth, Raises Guidance
- Avadel Pharmaceuticals’ Earnings Call Highlights Growth and Optimism
- Avadel Pharmaceuticals reports Q1 EPS (5c), consensus (7c)
- Avadel Pharmaceuticals sees FY25 revenue $255M-$265M, consensus $249.16M
- Avadel Pharmaceuticals sees Q2 revenue $60M-$63M, consensus $58.21M